ZLJ-33

N/A

Report date: 2022/02/15 16:47:24
NME

Base Information

Drug NameZLJ-33
Drug Alias NameZLJ-33
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor beta inhibitorsC-Raf kinase inhibitors
TargetsPlatelet-derived growth factor receptor betaC-Raf kinase
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInstitue Of Materia Medica Chinese Academy Of Medical Science
China Registration ClassN/A

Develop Information

Active CompaniesInstitue Of Materia Medica Chinese Academy Of Medical Science
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A